Millennium Velcade Supplement Seeks Full Approval, Second-Line Use
This article was originally published in The Pink Sheet Daily
Executive Summary
The company hopes to convert Velcade's accelerated approval for third-line use to full approval and add a second-line multiple myeloma indication based on the Phase III APEX trial, which showed a significant survival benefit.
You may also be interested in...
Velcade Phase III Studies Will Support First-Line Use, Millennium Says
The company expects to initiate three Phase III studies to support full approval of Velcade for treatment of multiple myeloma. FDA grants priority review designation to Velcade sNDA for second-line use, Millennium announces.
Velcade Phase III Studies Will Support First-Line Use, Millennium Says
The company expects to initiate three Phase III studies to support full approval of Velcade for treatment of multiple myeloma. FDA grants priority review designation to Velcade sNDA for second-line use, Millennium announces.
Industry Should Develop Narrower Indications First To Secure Market Access, AstraZeneca Exec Says
Demonstrating superiority to standard of care or placebo in narrower indications will win over regulators, AstraZeneca Exec-VP John Patterson says at R&D conference in Geneva, Switzerland. Millennium followed a similar strategy to develop Velcade.